Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00787319 |
To define what procedures were used for the diagnosis and monitoring of the treatment AMD. What is the effect of the Macugen, compliance with Macugen treatment, safety profile of Macugen, final physician assessment of treatment with Macugen.
Condition | Intervention | Phase |
---|---|---|
AMD |
Other: no intervention |
Phase IV |
Study Type: | Observational |
Study Design: | Case Control, Cross-Sectional |
Official Title: | Long-Term Non-Interventional Study (NIS) to Investigate the Safety and Effectiveness of MACUGEN in Patients With Neovascular Age-Related Macular Degeneration Under Conditions of Routine Clinical Practice |
Estimated Enrollment: | 120 |
Study Start Date: | November 2008 |
Estimated Study Completion Date: | June 2011 |
Estimated Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
AMD
outpatients with AMD
|
Other: no intervention
There is no intervention in this study. It is observational only.
|
no sampling
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
outpatients
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A5751032 |
Study First Received: | November 6, 2008 |
Last Updated: | November 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00787319 |
Health Authority: | Czech Republic: State Institute for Drug Control |
Ophthalmology, AMD, outpatients |
Eye Diseases Retinal Degeneration Macular Degeneration Retinal Diseases Retinal degeneration |